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Mismatched hematopoietic cell transplants for treating leukemia are complicated by
graft versus host disease (GvHD). Here, we show that adoptively transferred IL-12/15/
18-preactivated NK cells suppress GvHD in a mouse model of fully mismatched
hematopoietic cell transplantation. These IL-12/15/18-preactivated NK cells maintained
Eomesodermin (Eomes) and T-bet expression upon transfer and, while there was no
evidence of direct killing of donor T cells or host DCs by the IL-12/15/18-preactivated
NK cells, proliferation of donor T cells was inhibited. Strikingly, the graft versus leukemia
effect mediated by donor T cells was retained, resulting in improved overall survival of
mice that received lymphoma cells, donor allogeneic T cells, and IL-12/15/18-preactivated
NK cells. These results suggest that IL-12/15/18-preactivated NK cells may be useful in
improving immunotherapy of mismatched hematopoietic cell transplantation. Compared
with previously proposed protocols, our findings suggest that in vitro NK-cell preactiva-
tion with this cytokine cocktail offers the significant advantage that cytokines do not need
to be administered systemically to sustain NK-cell activity, thus avoiding toxicity.
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Introduction
During allogeneic HSC transplantation (HSCT), donor T cells and
natural killer (NK) cells cause graft versus leukemia (GvL), which
is a beneficial response toward destroying cancer cells. Donor
T cells, however, also react against host alloantigens on healthy
tissues, causing graft versus host disease (GvHD), which is a poten-
tially lethal condition andmust be managed with immunosuppres-
sive therapy. Different immunomodulatory modalities, including
immune cells, are being tested in order to improve the manage-
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ment of GvHD and retain the benefit of GvL. Grafted NK cells can
suppress GvHD and improve engraftment of HSCs in both mouse
models [1] and in patients [2]. They may do so by directly killing
activated T cells [3, 4], or by targeting host APCs [2], thereby sup-
pressing donor T-cell proliferation. Importantly, NK-cell-mediated
suppression of GvHD does not suppress GvL, which is retained [1,
2, 5]. One limitation for the use of adoptively transferred NK cells
in the clinic is the need for continuous stimulation with exoge-
nous cytokines (i.e. IL-2), which sustain NK-cell activity, but cause
unwanted toxicity. In order to avoid the toxicity of cytokine-based
therapies, strategies are being designed to preactivate NK cells
with cytokines in vitro prior to infusion into patients, thereby
eliminating the need to administer cytokines systemically. Adop-
tively transferred IL-12/15/18-preactivated NK cells (also termed
C© 2015 The Authors. European Journal of Immunology published byWiley-VCH Verlag GmbH & Co. KGaA,
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cytokine-induced memory-like NK cells) carry some of the proper-
ties of the recently defined “memory” or “long-lived” NK cells,
in that they proliferate upon adoptive transfer and are long-
lived [6–10], although they lack antigen-specific recall responses
[11, 12]. The ability to mount strong effector functions, alongside
their long life span in vivo and the lack of obvious side effects,
makes IL-12/15/18-preactivated NK cells attractive candidates
for cell-based immunotherapy. Indeed, IL-12/15/18-preactivated
NK cells have shown efficacy against cancer in mice [9]. Using
a mouse model of fully mismatched HSCT and lymphoma, we
assess here for the first time the ability of NK cells preactivated
with either IL-12/15/18 or IL-15 alone to suppress acute GvHD
without hampering GvL. Our results show that “memory-like”
IL-12/15/18-preactivated NK cells suppress GvHD but not GvL.
Results
IL-12/15/18-preactivated NK cells constitutively
produce IFN-γ and have an activated phenotype
We first quantified both degranulation (measured by expression
of extracellular CD107a on NK cells) and intracellular IFN-γ pro-
duction by IL-12/15/18-preactivated NK cells from C57BL/6 mice
(B6, H-2b) upon stimulation with PMA and ionomycin, or in
response to T-cell lymphoma YAC-1 cells or B-cell lymphoma A20
cells (Fig. 1A). Specific degranulation was calculated by subtract-
ing background degranulation (percentage of CD107a+ NK cells
in medium only; Fig. 1B). For comparison we also quantified both
degranulation and IFN-γ production by IL-15-preactivated NK cells
and NK cells activated with high doses of IL-2 for 7 days. Activa-
tion with high doses of IL-2 for 7 days is the standard procedure
to generate lymphokine-activated killer (LAK) cells, which medi-
ate potent killing activity. Background degranulation was higher
for IL-12/15/18-preactivated and IL-15-preactivated NK cells (7–
13%), than for IL-2-activatedNK cells (2%). Upon stimulationwith
tumor cells, specific degranulation of IL-15-preactivated NK cells
was two- to threefold higher (21–34%) than that of IL-12/15/18-
preactivated NK cells (9–11%). Specific degranulation of IL-2-
activated NK cells was at an intermediate level (16–24%; Fig. 1A
and B). In striking contrast, even in the absence of a stimulus,
IL-12/15/18-preactivated NK cells were the strongest IFN-γ pro-
ducers both in terms of percentage of IFN-γ positive NK cells
(100% of cells, compared to less than 3% among IL-15-
preactivated and IL-2-activated NK cells in the same condition;
Fig. 1C) and in terms of IFN-γ protein per cell, as indicated by the
higher fluorescence intensity (Fig. 1D). In essence, we infer that
IL-12/15/18-preactivated NK cells constitutively produce IFN-γ as
even in medium alone virtually all cells were IFN-γ+.
We next analyzed the phenotype of IL-12/15/18-preactivated
NK cells by flow cytometry in comparison to IL-15-preactivated
NK cells in order to assess the effect of the cytokines on the
expression of receptors, effector molecules, transcription factors,
and markers of maturity, activation, and differentiation (Fig. 2).
IL-12/15/18-preactivated NK cells upregulated FasL and Perforin,
Figure 1. IL-12/15/18-preactivated NK cells constitutively produce IFN-
γ. NK cells were purified from the spleens of B6mice and stimulated for
7 days with IL-2 (2000 IU/mL) or for 16–18 h with either IL-15 (10 ng/mL)
or IL-15 + IL-12 (10 ng/mL) + IL-18 (50 ng/mL). After careful washing,
they were cultured for additional 5 h in medium alone, or stimulated
with PMA and ionomycin, YAC-1 cells, or A20 cells (E:T ratio 1:1). Sub-
sequently, NK cells were stained and analyzed by flow cytometry by
gating on living singlet CD3− CD45+ NKp46+ NK1.1+ cells. (A) The per-
centages of CD107a+ NK cells are shown. (B) Specific NK-cell degran-
ulation (i.e. corrected for background degranulation) upon stimulation
with YAC-1 or A20 tumor cells, from (A). (C) The percentage of IFN-
γ+ NK cells from (A) is shown. (A–C) Data are shown as mean ± SD
of four samples pooled from four independent experiments with one
sample per group. (D) Representative dot plots (top) and histograms
(bottom) of IL-15-cultured and IL-12/15/18-preactivated NK cells cul-
tured in medium alone or activated with PMA and ionomycin, gating
on IFN-γ and CD107a (top) and IFN-γ (bottom). Statistical analysis was
done using one-way ANOVA followed by Dunnett’s multiple compar-
isons test.
as well as markers of activation (CD25 and Sca-1) and maturity
(CD11b and KLRG1). CD62L was downregulated, suggesting less
homing to LNs but rather to tissues. The transcription factor T-bet
was upregulated, which may explain the sustained IFN-γ produc-
tion. However, also Blimp-1 was upregulated, a transcription fac-
tor implicated as a negative regulator of cytokine production in
human NK cells [13].
IL-12/15/18-preactivated NK cells suppress acute
GvHD and maintain expression of Eomes and T-bet in
vivo
Adoptively transferred NK cells improve the outcome of HSCT
[1, 2] but are short lived unless stimulated with exogenous
cytokines, which cause adverse systemic effects. IL-15 may cause
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Figure 2. Phenotype of IL-12/15/18-
preactivated NK cells. NK cells were stimulated
with IL-15 or with IL-12/15/18 for 16–18 h.
They were subsequently washed, stained,
and analyzed by flow cytometry by gating
on living singlet CD3− CD45+ NKp46+ cells.
The phenotype of IL-12/15/18-preactivated
NK cells (black line histogram), IL-15-cultured
NK cells (dotted line histogram), and unstained
IL-12/15/18-preactivated NK cells as control
(gray-filled histogram) is shown. Histograms
are from one experiment representative of
n = 3 independent experiments, which gave
similar results.
less severe side effects and it is being explored as alternative to
IL-2. Although IL-15 may not generate long-lived NK cells, IL-12/
15/18-preactivated NK cells are long-lived in vivo and, upon
restimulation, respond vigorously for up to 3 weeks after the
first stimulation [6]. We reasoned that IL-12/15/18-preactivated
NK cells, based on their properties, could also improve the out-
come of HSCT and may mediate durable and beneficial effects
without the toxicity of exogenous cytokines. We therefore set out
to address the effect of IL-12/15/18-preactivated NK cells from B6
mice on acute GvHD in comparison with both IL-15-preactivated
NK cells and NK cells activated with IL-2, using a mouse model of
fully mismatched transplantation in which donor allogeneic T cells
from the spleens of B6 mice (H-2b) are adoptively transferred to
BALB/c mice (H-2d). In this model, BALB/c mice are lethally irra-
diated and receive myeloprotective T-cell depleted BM cells from
B6 mice. Figure 3A shows a scheme of the experimental setup.
Mice in Group 1 received allogeneic T cells and 20 of 21 mice
died of acute GvHD within 7 days (Fig. 3B). Mice in Group 2
received IL-2-activated NK cells from B6 mice in addition to allo-
geneic T cells and all eight mice died of acute GvHD within 7 days
(Fig. 3B). In striking contrast, only 3 of 10 and none of 11 mice
died within 7 days in Group 3 and Group 4, respectively, which
received IL-15- or IL-12/15/18-preactivated NK cells alongside
allogeneic T cells. Indeed, 6 of 10 and 9 of 11 mice in these groups
were still alive at day 14 post-transfer (Fig. 3B). Importantly,
the clinical score (denoting severity of acute GvHD) was low-
est for both these groups. These results show that both IL-15- and
IL-12/15/18-preactivated NK cells, but not IL-2-activated NK cells,
strongly suppress acute GvHD and improve overall survival in our
mouse model.
NK cells activated with IL-2 in vitro do suppress acute GvHD
upon adoptive transfer [5], however they also become exhausted
and lose expression of Eomesodermin (Eomes) and T-bet [14].
We thus carried out an additional experiment to investigate if
IL-12/15/18-preactivated NK cells also become exhausted. Mice
were treated as in Figure 3A Group 1 and Group 3, and NK cells
were reisolated at 4 days after transfer. NK cells present in mice
from Group 1 are derived from the transplanted BM cells and can
be found in the spleen and other organs of recipient mice. Inter-
estingly, IL-12/15/18-preactivated NK cells still expressed Eomes
and T-bet, despite downregulation of the early activation marker
CD69 and partial downregulation of CD25 (Fig. 3C) at this time
point. This indicated that NK cells preactivated with IL-12/15/18
do not become exhausted upon adoptive transfer.
IL-12/15/18-preactivated NK cells reduce donor
chimerism and inhibit proliferation of donor T cells
To investigate themechanisms bywhich IL-12/15/18-preactivated
NK cells suppress GvHD, we quantified cell numbers in the spleens
of mice on day 5 after irradiation and transfer, using the same
model as in Figure 3. Thus, one group of mice received no
NK cells, one group received IL-2-activated NK cells, and the last
C© 2015 The Authors. European Journal of Immunology published by
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
1730 Christian M. Hu¨ber et al. Eur. J. Immunol. 2015. 45: 1727–1735
Figure 3. IL-12/15/18-preactivated NK cells suppress acute GvHD.
(A) The experimental design. BALB/c host mice were lethally irradi-
ated and received myeloprotective T-cell depleted BMCs from B6 mice.
They also received freshly purified splenic allogeneic T cells from B6
mice (basic treatment, Group 1). Mice in Group 2 additionally received
IL-2-activated NK cells. Mice in Group 3 additionally received IL-15-
preactivated NK cells, whereas mice in Group 4 additionally received
IL-12/15/18-preactivated NK cells. (B) Survival curves and clinical scores
ofmice from the three treatment groupsweremonitored over time. Sta-
tistical analysis of survival was done using log-rank test; Group 1 versus
Group 2: ns (p = 0.0817); Group 1 versus Group 3: ***p = 0.0001; Group 1
versus Group 4: ****p < 0.0001; Group 3 versus Group 4: ns (p = 0.2146).
Clinical scores are shown as mean ± SD of n = 8–21 mice per group
pooled fromat least two independent experiments. Clinical scoreswere
compared applying one-wayANOVA followed byTukey’smultiple com-
parisons test for statistical analysis. (C) NK cells were reisolated from
spleens of mice in Group 1 and Group 3 at 4 days postirradiation and
injection, and analyzed for Eomes, T-bet, CD69, and CD25 expression
by flow cytometry. The phenotype of NK cells from untreated control
B6 mice (gray-filled histogram), non-NK/NKT cells from untreated con-
trol B6 mice (thin dotted line histogram), NK cells from mice in Group
1 (thick dashed line histogram) that are derived from the transplanted
BM, and IL-12/15/18-preactivated NK cells from mice in Group 3 (thick
line histogram) is shown. Histograms are representatives of n = 9 mice
analyzed in two independent experiments.
group received IL-12/15/18-preactivated NK cells. All mice also
received allogeneic T cells from B6 mice. On day 5 postirradiation
and transfer, the total number of splenocytes was approximately
half in those mice receiving IL-12/15/18-preactivated NK cells,
when compared to total splenocyte numbers in mice receiving
either no NK cells or IL-2-activated NK cells (Fig. 4A). The reduc-
tion in total cell numbers was due to lower numbers of H-2Kb+
donor cells, which were four- to fivefold reduced compared to
host mice that received no NK cells or IL-2-activated NK cells
(Fig. 4A). On the other hand, the number of H-2Kd+ host cells
in mice receiving IL-12/15/18-preactivated NK cells was about
twofold greater than in mice receiving either no NK cells or IL-2-
activated NK cells. Therefore, we infer that adoptively transferred
IL-12/15/18-preactivated NK cells lower the donor chimerism and
preserve host cells.
Grafted donor cells are able to kill allogeneic host cells, due
to allorecognition. Host DCs present alloantigens to donor T cells,
which causes donor T-cell activation and proliferation. A lower
number of host DCs normally leads to reduced alloactivation
of donor T cells and may therefore reduce the GvHD effect.
Since mice that received IL-12/15/18-preactivated NK cells devel-
oped a milder form of GvHD, we hypothesized that IL-12/15/18-
preactivated NK cells may kill host DCs. For that reason, we mea-
sured numbers and activation of host DCs in mice from each
of the three treatment groups. Contrary to our hypothesis, we
noticed that mice receiving IL-12/15/18-preactivated NK cells had
an approximately twofold increase in the number of host DCs,
which expressed lower levels of CD11c and higher levels of MHC
class II molecules (Fig. 4A). In these mice, the number of donor
NK cells recovered was over 40-fold higher (>106 IL-12/15/18-
preactivated NK cells recovered per spleen) than in mice receiving
IL-2-activated NK cells (Fig. 4A). Donor T cells (both CD4+ and
CD8+) were reduced by 85–90% in mice receiving IL-12/15/18-
preactivated NK cells compared to mice receiving IL-2-activated
NK cells (Fig. 4A). Analysis of CFSE dilution in donor T cells indi-
cated that T-cell proliferation was strongly reduced in the pres-
ence of IL-12/15/18-preactivated NK cells. Indeed, the propor-
tion of undivided CD8+ and CD4+ T cells was strongly increased
on day 4 and day 5 in mice receiving IL-12/15/18-preactivated
NK cells, compared to mice that did not receive NK cells (Fig. 4B).
Upregulation of CD25 on T cells ex vivo at day 4 post-transplant
was strongly reduced in mice receiving IL-12/15/18-preactivated
NK cells (Supporting Information Fig. 1). Additionally, the num-
ber of Treg cells was significantly reduced in mice that received IL-
12/15/18-preactivated NK cells (Supporting Information Fig. 2).
This indicates that the reduction in acute GvHD severity observed
in mice with IL-12/15/18-preactivated NK cells is not due to an
increased number of Treg cells.
Collectively, these results suggest that IL-12/15/18-
preactivated NK cells do not kill host DCs, but may rather
promote their activation, presumably through the abundant pro-
duction of IFN-γ. On the other hand, IL-12/15/18-preactivated
NK cells inhibit proliferation and activation of donor T cells.
This could contribute to the observed suppression of acute
GvHD mediated by IL-12/15/18-preactivated NK cells. Another
mechanism by which IL-12/15/18-preactivated NK cells may
suppress acute GvHD could be via direct killing of donor T cells,
which become activated by host alloantigens.
IL-12/15/18-preactivated NK cells do not degranulate
in response to allogeneic host or syngeneic donor cells
We directly measured degranulation of IL-12/15/18-preactivated
NK cells upon stimulation with allogeneic target cells and com-
pared it to degranulation of IL-15-preactivated NK cells and of
NK cells activated with high doses of IL-2 for 7 days. Target
cells were either LPS-matured BMDCs or splenocytes stimulated
C© 2015 The Authors. European Journal of Immunology published by
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Figure 4. IL-12/15/18-preactivated NK cells
reduce donor chimerism and inhibit prolifera-
tion of donor T cells. Mice were treated as in
Fig. 3A, except that in this experiment donor
allogeneic T cells were CFSE-labeled prior to
injection. (A) The number of the indicated
type of cells per mouse spleen or GMFI (geo-
metric mean fluorescence intensity) on day 5
was determined by flow cytometry. Gating per-
formed on living CD45+ singlet cells. Discrimi-
nation between host and donor cells was done
by H-2Kb (donor)/H-2Kd (host) staining. White
bars indicate cells from BALB/c mice (host),
whereas dark bars indicate cells from B6 mice
(donor). T cells were identified as CD3+, NK1.1−,
and either CD4+ or CD8+; NK cells were identi-
fied as CD3−, NKp46+, NK1.1+; DCs were iden-
tified as CD3−, NK1.1−, CD19−, CD11c+, I-A/I-
E+. Data are shown as the mean ± SD of n =
7–8 mice per group pooled from two indepen-
dent experiments. Statistical analysis was done
using one-way ANOVA followed by Tukey’s
multiple comparisons test. (B) CFSE dilution of
donor CD4+ or CD8+ T cells formice that did not
receive NK cells (top) or received IL-12/15/18-
preactivated NK cells (bottom) was analyzed
by flow cytometry 4 or 5 days postirradiation
and injection. Histograms are representative for
n = 7–9 mice/group pooled from two indepen-
dent experiments for each of the two time
points.
with concanavalin A (ConA), which contain mostly activated
T cells (Fig. 5A). Both target cells were allogeneic (from BALB/c
mice). Upon stimulation with either allogeneic BMDCs or allo-
geneic ConA blasts, specific degranulation was <10%, irrespec-
tive of whether cells were preactivated with IL-12/15/18, IL-15, or
activated with IL-2 (Fig. 5C). These results confirm that allogeneic
cells do not trigger degranulation in IL-12/15/18-preactivated
NK cells, which most likely do not kill host cells in vivo.
We show in Figure 4B that IL-12/15/18-preactivated NK cells
inhibit proliferation of donor T cells in vivo. In order to test the
ability of IL-12/15/18-preactivated NK cells to kill donor T cells,
we activated donor T cells in vivo by transferring splenic T cells
from B6 mice into lethally irradiated allogeneic BALB/c mice.
After 5 days, we explanted donor T cells from the spleen of host
mice and tested the ability of these T cells, previously activated
in vivo by alloantigens, to stimulate degranulation in syngeneic
IL-12/15/18-preactivated NK cells and in IL-2-activated NK cells
(Fig. 5B). As control targets, we also used unstimulated na¨ıve
T cells from the spleens of B6 mice. There was essentially no spe-
cific degranulation in response to either na¨ıve T cells or to in vivo
activated T cells either by IL-12/15/18-preactivated NK cells or
by IL-2-activated NK cells (Fig. 5D). Taken together, these results
indicate that IL-12/15/18-preactivated NK cells do not directly kill
alloactivated T cells. Indeed, no sign of cell death was observed
C© 2015 The Authors. European Journal of Immunology published by
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Figure 5. NK-cell degranulation upon stimulation with allogeneic or
syngeneic target cells. NK cells from B6 mice were purified and stimu-
lated as described in Fig. 1 and used as effector cells in a degranulation
assay. NK cellswere analyzed by flow cytometry and gated on living sin-
glet CD3−, CD45+, NKp46+, NK1.1+, H-2Kb+ cells. (A, B) The generation
of target cells is shown. (A) Allogeneic target cells fromBALB/cmice. BM
cells were isolated from BALB/c mice, differentiated with GM-CSF, and
maturated with LPS in vitro. ConA blasts were generated by activating
BALB/c splenocytes with ConA. (B) Syngeneic target cells from B6 mice.
B6 T cells were freshly purified and used as control target cells. Alter-
natively, they were injected into lethally irradiated BALB/c host mice,
causing them to expand due to alloactivation. BALB/c host mice were
culled after 5 days and alloactivated donor T cells were purified. (C) The
percentage of CD107a+ NK cells (i.e. degranulating; top) and specific
degranulation (i.e. corrected for degranulation in absence of stimulus;
bottom) for IL-2-activated NK cells or IL-15-preactivated or IL-12/15/18-
preactivated NK cells stimulated with the indicated stimuli. Data are
shownasmean±SDof n= 4 independent experimentswith one sample
per group and experiment. Statistical analysis was done using one-way
ANOVA followedbyDunnett’smultiple comparisons test. (D) Performed
as in (C), but with fresh T cells or alloactivated T cells as target cells.
Data are shown as mean ± SD of n = 3 independent experiments with
one sample per group and experiment. Statistical analysis was done
using unpaired two-tailed t-test.
in either na¨ıve or activated T cells after the 5-h assay period (data
not shown).
Suppression of GvHD by IL-12/15/18-preactivated
NK cells is compatible with effective GvL
Donor CD8+ T cells kill host tumor cells and are the main medi-
ators of GvL [15]. IL-12/15/18-preactivated NK cells have been
Figure 6. IL-12/15/18-preactivated NK cells in GvHD and GvL. (A) The
experimental design. BALB/c host mice were lethally irradiated. All
mice received myeloprotective T-cell depleted allogeneic BM cells from
B6 mice plus syngeneic A20 lymphoma cells. Mice in Groups 2 and 3
also received splenic T cells from B6 mice. Mice in Group 3 additionally
received IL-12/15/18-preactivated NK cells from B6 mice. (B) Survival
over time and clinical scores shown as mean ± SD of mice from the
three treatment groupswith n= 8mice per group from two independent
experiments. Statistical analysis of survival using log-rank test; Group
1 versus Group 2: ****p < 0.0001; Group 1 versus Group 3: *p = 0.0240;
Group 2 versus Group 3: **p = 0.0023. Clinical scores were compared
applying one-way ANOVA followed by Tukey’s multiple comparisons
test for statistical analysis.
shown to reduce the growth of solid tumors in mice, when com-
bined with radiotherapy [9]. However, in our model of lymphoma,
no effect on survival was observed when lymphoma-bearing mice
were treated with IL-12/15/18-preactivated NK cells (Supporting
Information Fig. 3A), suggesting that IL-12/15/18-preactivated
NK cells are not able to mediate GvL in our model. However, when
tumor cells and IL-12/15/18-preactivated NK cells were simulta-
neously coinjected, the IL-12/15/18-preactivated NK cells signif-
icantly delayed progression (p < 0.0001), although tumors were
not cleared and all mice died 1.5 days (median) after the control
group (Supporting Information Fig. 3B).
The ability of IL-12/15/18-preactivated NK cells to inhibit
donor T-cell proliferation (Fig. 4) could interfere with T-cell-
mediated GvL. To test this directly, we used the same model of
fully mismatched transplantation as in Figure 3A but this time also
administered A20 lymphoma cells (Fig. 6A). Mice that received
A20 cells but no allogeneic T cells developed tumors in spleen and
liver and all (8/8) died within 19 days (Group 1, Fig. 6B). All
mice (8/8) that received A20 cells and allogeneic donor T cells
succumbed to acute GvHD within 7 days (Group 2, Fig. 6B).
In contrast, mice that received A20 cells, allogeneic T cells, and
IL-12/15/18-preactivated NK cells survived significantly longer
(Group 3, Fig. 6B). In this group, the clinical score for GvHD
ranged from 0 to 4 and was therefore much lower than the clini-
cal score of 5–6 for mice in Group 2. Strikingly, the remaining six
of eight mice all survived the critical phase of days 15–19, when
none of the eight mice in Group 1 survived due to the A20 tumors.
This result clearly shows that IL-12/15/18-preactivated NK cells
suppress GvHD but not GvL. Indeed, we found no remaining tumor
cells at the postmortem analysis (data not shown). The surviving
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six mice, however, had developed late weight loss, reduced activ-
ity, and pallor by 40 days and the cellularity of the BM was very
low (around 105 cells per femur and tibia combined; data not
shown). These signs are compatible with chronic GvHD and with
BM failure due to suboptimal engraftment.
Discussion
We show here that IL-12/15/18-preactivated NK cells sustain
expression of Eomes and T-bet and suppress acute GVHD but not
GvL in a mouse model of fully mismatched HSCT and lymphoma.
We also show that IL-2-activated NK cells do not have a significant
impact on acute GvHD or on survival in our model, which is in line
with previous findings that IL-2-activated NK cells become aner-
gic due to downregulation of Eomes and T-bet [1, 14]. The sus-
tained expression of Eomes and T-bet in IL-12/15/18-preactivated
NK cellsmay explain their proliferative potential upon transfer into
mice. Indeed, inmice receiving IL-12/15/18-preactivated NK cells,
the number of NK cells recovered 5 days after transfer was far
higher than in mice that had received IL-2-activated NK cells. The
numbers of IL-12/15/18-preactivated NK cells recovered in the
spleen alone were greater than the 106 cells injected, indicating
strong proliferation. Although we did not analyze long-term sur-
vival of these NK cells, the fact that acute GvHD was strongly
inhibited and that mice survived for several weeks indicates that
IL-12/15/18-preactivated NK cells may persist for longer periods.
This is in line with a previous report showing that IL-12/15/18-
preactivated NK cells are long-lived [6].
NK cells have been implicated before in the suppression of
GvHD by two mechanisms: either by direct killing of donor T cells,
which are activated by alloantigens and may upregulate ligands
for NK-cell receptors DNAM-1 and NKG2D [16, 17], or by killing
host DCs hence inhibiting donor T-cell proliferation [2]. Simi-
larly, cytokine-stimulated human CD56bright NK cells efficiently
killed activated autologous CD4+ T cells in vitro [3]. We found
that, in our model, IL-12/15/18-preactivated NK cells did not kill
either host DCs or donor T cells activated in vivo by alloantigens,
and neither did they upregulate DNAM-1 nor NKG2D. Moreover,
the donor chimerism was lower in the presence of IL-12/15/18-
preactivated NK cells and host cells were preserved. The low donor
chimerism may reflect low engraftment of donor HSCs. Indeed,
mice that survived acute GvHD developed signs of anemia and
showed very low BM cell counts at up to 6 weeks after irradiation.
It is unclear as to whether this is a sign of suboptimal engraftment
or of chronic GvHD.
IL-12/15/18-preactivated NK cells upregulated Perforin and
FasL in vitro, thus potentially enhancing cytotoxicity, but they
did not vigorously degranulate in response to any of the tar-
gets tested, including YAC-1 and A20 lymphomas, LPS-matured
allogeneic BMDCs, ConA-activated allogeneic T cells, or na¨ıve or
alloantigen-activated syngeneic T cells. Hence, the mechanism by
which IL-12/15/18-preactivated NK cells suppressed GvHD is nei-
ther through killing host DCs nor by directly killing donor T cells.
In addition to the poor degranulation of IL-12/15/18-preactivated
NK cells in response to YAC-1 and A20 cells, we also found that
IL-12/15/18-preactivated NK cells are not able to prolong sur-
vival of tumor-bearing mice, although they can significantly delay
progression when coinjected with tumor cells. This may be due
to IFN-γ, which was shown to have not only a beneficial impact
on acute GvHD, but also direct antitumor effects and to improve
the ability of allogeneic donor T cells to kill host tumor cells
[18]. Ni et al. showed that, in combination with radiotherapy,
IL-12/15/18-preactivated NK cells reduced tumor growth and pro-
longed survival of mice with established tumors [9]. Given the
different tumor models and route of administration, a direct com-
parison between the two data sets is difficult: we injected A20
lymphoma cells i.v., whereas Ni et al. administered RMA-S cells
subcutaneously and, in another model, they evaluated lung clear-
ance upon i.v. injection of B16-RAE-1ε melanoma cells. Interest-
ingly, production of IFN-γ and not perforin-mediated killing is the
essential NK-cell effector function to limit lung metastases caused
by B16 melanoma cells in mice [19]. Moreover, radiotherapy
both initiated reduction of tumor growth and induced homing of
IL-12/15/18-preactivated NK cells to the localized tumors [9],
which we could not obtain due to the systemic spread of A20
tumors. Finally, in Ni et al. it was shown that host CD4+
T cells were necessary for the antitumor activity of IL-12/15/18-
preactivated NK cells [9]. The absence of host CD4+ T cells in
lethally irradiated BALB/c mice may thus be another reason why
IL-12/15/18-preactivated NK cells did not improve survival of
tumor-bearing mice.
IL-12/15/18-preactivated NK cells upregulated T-bet, constitu-
tively produced IFN-γ and, upon transfer, might activate host DCs,
which in turn may drive donor T-cell proliferation. Although we
found evidence of DC activation (CD11clow and MHC class IIhigh)
by IL-12/15/18-preactivated NK cells, donor T-cell proliferation
in vivo was actually inhibited by IL-12/15/18-preactivated donor
NK cells. The mechanisms by which this inhibition occurred may
well contribute to suppressing GvHD, but remains to be defined,
although it is likely that upregulation of the high-affinity receptor
for IL-2 (CD25) on IL-12/15/18-preactivated NK cells makes them
sequester IL-2 by which they may outcompete donor T cells [20].
In patients suffering from chronic GvHD, treatment with low-dose
IL-2 enhanced Treg-cell counts and significantly suppressed clini-
cal signs of chronic GvHD [21]. In our mouse model, IL-12/15/18-
preactivated NK cells may also outcompete Treg cells for IL-2,
and indeed Treg cells were decreased in mice that had received
IL-12/15/18-preactivated NK cells. However, the reduction in
Treg cells did not cause an increased severity of acute GvHD.
The protocol explored preclinically here offers the significant
advantage of not requiring systemic cytokine administration to
sustain the beneficial effects of NK cells. It will be interesting to
assess whether the IL-12/15/18-preactivated NK cells and low-
dose IL-2, which is known to enhance Treg cells, might be sequen-
tially combined to suppress both acute and chronic GvHD.
C© 2015 The Authors. European Journal of Immunology published by
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Materials and methods
Mice
C57BL/6 (referred to as B6) and BALB/c mice were purchased
from Charles River, UK. All mice were female, used at 8–12 weeks
of age and housed at the University of Cambridge Central Biomed-
ical Services under pathogen-free conditions and according to UK
Home Office guidelines. Animal studies have been reviewed and
approved by the UK Home Office.
Cell line
A20 cells (BALB/c B cell lymphoma, H-2d), a gift of Profes-
sor K. Smith, and YAC-1 cells, were maintained in RPMI-1640
medium with stable Glutamine and supplemented with peni-
cillin/streptomycin (all PAA), 10% FBS (Life technologies), and
50 μM β-mercaptoethanol (Sigma).
GvHD and GvL
BALB/c host mice were lethally irradiated (two doses of 4.5 Gy,
3 h apart from each other) and 3 h later injected i.v. with 5 ×
106 T-cell-depleted BMCs from B6 mice. T-cell-depleted BMCs are
myeloprotective. Where indicated, mice were also injected with 1
× 106 purified splenic T cells from B6 mice, which cause GvHD,
and/or 1 × 106 purified and stimulated NK cells (also from B6
spleens). In GvL experiments, mice additionally received 5 × 104
A20 cells (2.5 × 104 in Supporting Information Fig. 3A where
injection was 5 days before irradiation). The GvHD clinical score
was assessed on day 5 postirradiation and based on mouse weight
loss (0–2), posture (0–2), activity (0–2), and fur texture (0–2),
giving a maximum clinical score of 8. Mice were culled before
reaching 25% weight loss.
Cell purification and stimulation
Magnetic beads (CD3 Microbead kit, Pan T Cell Isolation kit II,
NK cell isolation kit II; Miltenyi Biotec) were used to deplete T cells
in BMCs and to purify donor T cells and donor NK cells from
spleens (purity > 90%). Where indicated, NK cells were stimu-
lated for 16– 18 h with 2000 IU/mL rhIL-2 (Proleukin, Novartis),
10 ng/mL rmIL-15 (PeproTech), or 10 ng/mL rmIL-12 (Pepro-
Tech) + 10 ng/mL IL-15 + 50 ng/mL rmIL-18 (MBL) or for 7 days
with 2000 IU/mL rhIL-2. We found that it is important to wash
NK cells thoroughly after preactivation, that is at least three times
with a large volume of PBS. LPS-matured BMDCs were generated
as previously described [22]. ConA blasts were generated by cul-
turing single cell suspensions from BALB/c spleens for 30 min at
37°C, then collecting nonadherent cells. Nonadherent cells were
cultured with 5 μg/mL ConA (Sigma) for 48–72 h before used.
Degranulation assay
Degranulation assays were performed in 96-well tissue culture
treated U-bottom plates. A total of 2 × 105–3 × 105 NK cells
were plated per well and 1 μg/mL PE-conjugated anti-CD107a
antibody was added. Where indicated, medium alone, target cells
(effector:target ratio 1:1), or PMA (100 ng/mL, Sigma) + iono-
mycin (2 μg/mL, Sigma) were added to a total volume of 200 μL
and incubated at 37°C. After 1 h, Brefeldin A (3 μg/mL, eBio-
science) and Monensin (5 μM, Sigma) were added. Cells were
then cultured for additional 4 h, subsequently pelleted, washed,
and stained for analysis by flow cytometry.
Flow cytometry
Conjugated mAbs anti-mouse CD45 (30-F11), CD3ε (17A2),
H-2Kb (AF6-88.5), H-2Kd (SF1-1.1), NKG2D (CX5), FasL (MFL3),
TRAIL (N2B2), DNAM-1 (TX42.1), Ly49D (4E5), CD25 (PC61),
Perforin (eBioOMAK-D), Sca-1 (D7), PD-1 (29F.1A12), 2B4
(eBio244F4), KLRG1 (2F1), CD11b (M1/70), CD11c (N418),
CD27 (LG.3A10), Thy1.2 (30-H12), CD62L (MEL-14), CD44
(IM7), NKp46 (29A1.4), NK1.1 (PK136), CD4 (RM4-5), CD8α
(53-6.7), IFN-γ (XMG1.2), Eomes (Dan11mag), T-bet (O4-46),
Blimp-1 (5E7), CD107a (1D4B), Foxp3 (NRRF-30), CD16/32-Fc
blocking (93), and anti-human/mouse Granzyme B (GB11) were
purchased from BioLegend, eBioscience, and BD Pharmingen.
Intracellular staining was done using the Foxp3 staining buffer
set (eBioscience). DAPI (Life technologies) or fixable viability dye
eFluor 450 or eFluor 506 (eBioscience) was used to exclude dead
cells. Sample acquisition was done on a BD LSR Fortessa (BD
Biosciences) using BD FACS Diva software (BD Biosciences) and
analyzed using FlowJo (Tree Star).
Statistical analysis
Statistical analysis was done using GraphPad Prism 6 software.
Log-rank test, two-tailed unpaired t-test, or ordinary one- or two-
way ANOVA followed by Tukey’s or Dunnett’s multiple compar-
isons test was used to investigate statistical significance, whichwas
defined as p < 0.05. Data are expressed as means ± SD. Asterisks
indicate level of significance (*p< 0.05, **p< 0.01, ***p< 0.001,
****p < 0.0001).
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